文献速递白血病

成人急性髓系白血病非移植随机对照试验 eligibility 标准的演变

Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia.
PubMed 文献 · Leukemia · 2022-06-03

研究分析2010至2020年间75项成人急性髓系白血病非移植治疗的三期随机对照试验,发现仅41%报告未入组信息,中位未入组率23%,主要归因于限制性 eligibility 标准;eligibility 标准数量随时间增加(P < 0.001),与ASCO-Friends推荐的一致性从35%到99%不等。

要点

  • 75项三期随机对照试验中仅31项(41%)报告未入组信息,中位未入组率23%。
  • eligibility 标准数量随时间增加(P < 0.001),尤其在产业资助试验中。
  • 与ASCO-Friends推荐的一致性差异大,范围35%至99%。

核心结论

  • 非移植随机对照试验结果的外推能力可能因高未入组率和日益严格的 eligibility 标准而逐渐受限。

研究设计与样本

  • 从2010至2020年发表的3698项研究中识别出75项成人急性髓系白血病非移植治疗的三期随机对照试验。

主要发现

  • 仅31项研究(41%)提供未入组信息,这些研究中位未入组率为23%,主要归因于限制性 eligibility 标准。
  • 95%的试验报告了 eligibility 标准,每项试验的标准总数随时间增加(P < 0.001),尤其在产业资助试验中。
  • 共使用27项 eligibility 标准,大多涉及合并症或体能状态,其中8项随时间变得更常见。
  • 与近期ASCO-Friends of Cancer Research eligibility 标准推荐的一致性差异大,从35%到99%不等。

关键数值与推荐

  • 中位未入组率为23%,归因于限制性 eligibility 标准。
  • eligibility 标准总数随时间增加(P < 0.001)。
  • 与ASCO-Friends推荐的一致性范围为35%至99%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Eligibility criteria for clinical trials are intended to select suitable study subjects but can limit trial participation and generalization of results. While reported for other cancers, non-enrollment rates and evolution of eligibility criteria over time have so far not been studied for randomized controlled trials (RCTs) involving adults with acute myeloid leukemia (AML). Among 3698 studies published between 2010 and 2020, including 447 involving prospective clinical trials, we identified 75 phase three RCTs testing non-transplant therapies for adults with AML. Only 31 studies (41%) provided information on non-enrollment; in these studies, the median non-enrollment rate was 23%, primarily attributed to restrictive eligibility criteria. In 95% of trials, eligibility criteria were reported with the total number per trial increasing over time (P < 0.001), particularly in industry-funded trials. A total of 27 eligibility criteria were used across trials, mostly concerning comorbidities or performance status, with eight of them becoming more common over time. The concordance with recent ASCO - Friends of Cancer Research eligibility criteria recommendations greatly varied, from 35% to 99%. Together, our analyses suggest that the ability to generalize results from non-transplant RCTs may be increasingly limited because of high non-enrollment rates and increasingly restrictive eligibility criteria.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Orvain C, Othus M, Johal G, et al. Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia. Leukemia. 2022. PMID: 35660798. doi:10.1038/s41375-022-01624-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。